CDK Inhibitor Patent Landscape 2009

Table of Contents

METHODOLOGY

INTRODUCTION

1. BRIEF OUTLINE OF THE PIPELINE

2. PROTECTION STRATEGIES

• 2.1. Evolution of patent filings over time
• 2.2. Priority filings
• 2.3.Extensions
• 2.4. Analysis of industrial patents over time
• 2.5. Study of the granting of US patents
• 2.6. Study of the granting of European patents
• 2.7. Evolution in the number of applicants

3. TOPOLOGY OF PATENTS IN THE SECTOR

• 3.1. Breakdown of patents into classes of CDK inhibitors
• 3.2. Breakdown of patents into types of targeted CDK
• 3.3. Cross analysis of the categories "classes of CDK inhibitors" and "types of targeted CDK"

4. ANALYSIS OF THE MAIN APPLICANTS

• 4.1. Main applicants
• 4.2. Filings by main applicants over time
• 4.3. Focus on the global strategy of the major industrial applicants
• 4.4. Topics protected
• 4.5.Collaborations
• 4.6. Citations between applicants
• 4.7. Emerging applicants

5. ANALYSIS OF THE MAIN INVENTORS

• 5.1. Main inventors
• 5.2. Topics protected
• 5.3. Research teams
• 5.4. Experts
• 5.5. Emerging inventors

CONCLUSION

APPENDIX 1: APPLICANTS WITH ACTIVE CLINICAL TRIALS AND THEIR NUMBER OF PATENT FILINGS

APPENDIX 2: PATENT FILINGS OF APPLICANTS BY MAIN TOPICS

APPENDIX 3: NUMBER OF PATENT FILINGS PER APPLICANTS

List of Figures

• FIGURE 1 - SCHEMATIC REGULATION OF THE CDK-CYCLIN COMPLEX
• FIGURE 2 - THE CELL CYCLE AND ITS REGULATION BY CDK
• FIGURE 3 - CDK INHIBITORS UNDER DEVELOPMENT BY CLASS OF COMPOUNDS (AUGUST 2009)
• FIGURE 4 - EVOLUTION IN PATENT FILINGS
• FIGURE 5 - GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS
• FIGURE 6 - GEOGRAPHIC DISTRIBUTION OF EXTENSIONS
• FIGURE 7 - EVOLUTION OF THE BREAKDOWN OF INDUSTRIAL PATENTS
• FIGURE 8 - EVOLUTION OF AVERAGE GRANT TIME FOR US PATENTS
• FIGURE 9 - EVOLUTION OF THE GRANTING OF US PATENTS
• FIGURE 10 - EVOLUTION OF AVERAGE GRANT TIME FOR EUROPEAN PATENTS
• FIGURE 11 - EVOLUTION OF AVERAGE GRANT TIME FOR EUROPEAN PATENTS
• FIGURE 12 - EVOLUTION OF THE NUMBER OF APPLICANTS
• FIGURE 13 - BREAKDOWN OF THE PORTFOLIO BY CLASSES OF COMPOUNDS
• FIGURE 14 - BREAKDOWN OF THE PORTFOLIO BY TYPES OF TARGETED CDK
• FIGURE 15 - CROSS-ANALYSIS OF THE CATEGORIES "CLASSES OF CDK INHIBITORS" AND "TYPES OF TARGETED CDK"
• FIGURE 16 - MAIN APPLICANTS IN THE ENTIRE PORTFOLIO
• FIGURE 17 - BREAKDOWN OF THE MAIN PATENT PORTFOLIOS
• FIGURE 18 - EXTENSION POLICY FOR THE FIVE MAJOR INDUSTRIAL PLAYERS
• FIGURE 19 - CLASSES OF CDK INHIBITORS BY MAIN APPLICANTS
• FIGURE 20 - TYPES OF TARGETED CDK BY MAIN APPLICANTS
• FIGURE 21 - MAIN PLAYERS POSITIONED ON THE DEVELOPMENT OF SCREENING METHODS, COMBINATIONS AND OLIGONUCLEOTIDES (>3 FILINGS)
• FIGURE 22 - MAJOR COLLABORATIONS AND JOINT-FILINGS
• FIGURE 23 - MAP OF CITATIONS BETWEEN APPLICANTS
• FIGURE 24 - CLASSES OF CDK INHIBITORS BY MAIN INVENTORS
• FIGURE 25 - TYPES OF TARGETED CDK BY MAIN INVENTORS
• FIGURE 26 - MAIN RESEARCH TEAM
• FIGURE 27 - LIST OF EXPERT

List of Tables

• TABLE 1 - CYCLIN DEPENDENT KINASES INVOLVED IN DISEASES OR REPRODUCTION
• TABLE 2 - EVOLUTION OF PRIORITY FILINGS
• TABLE 3 - EVOLUTION OF EXTENSIONS
• TABLE 4 - DESCRIPTION OF THE CLASSES OF COMPOUNDS USED TO BREAK DOWN THE PORTFOLIO
• TABLE 5 - BREAKDOWN BY CLASSES OF CDK INHIBITORS OVER TIME
• TABLE 6 - BREAKDOWN BY SCREENING METHODS, COMBINATIONS AND OLIGONUCLEOTIDES OVER TIME
• TABLE 7 - BREAKDOWN BY CLASSES OF CDK INHIBITORS OVER TIME
• TABLE 8 - BREAKDOWN OF FILINGS BY MAIN APPLICANTS OVER TIME
• TABLE 9 - EMERGING APPLICANTS
• TABLE 10 -LIST OF THE MAIN INVENTORS
• TABLE 11 -EMERGING INVENTORS